✦ LIBER ✦

0-70. The addition of surgery to tamoxifen as primary treatment of early breast cancer in women over 70, a multicentre trial

✍ Scribed by J. Latteier; T. Bates; D.L. Riley; J. Houghton; M. Baum

Book ID: 114317076
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 153 KB
Volume: 6
Category: Article
ISSN: 0960-9776
DOI: 10.1016/s0960-9776(97)90651-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Late follow-up of a randomized trial of

Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer

✍ M. Fennessy; T. Bates; K. MacRae; D. Riley; J. Houghton; M. Baum 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## Abstract ## Background Breast cancer has been considered a more indolent disease in the elderly, who are less tolerant of aggressive therapy. This trial tested the hypothesis that tamoxifen without surgery would provide adequate control of breast cancer for the remainder of life in elderly wome

1–44 Late Follow-up of a Randomized Tria

1–44 Late Follow-up of a Randomized Trial of Surgery Plus Tamoxifen Versus Tamoxifen Alone in Women Aged Over 70 Years With Operable Breast Cancer

✍ Kommareddy, A.; Ellis, M.J. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 114 KB

A randomised trial comparing tamoxifen v

A randomised trial comparing tamoxifen vs. surgery in patients over the age of 70 with operable breast cancer - Final results after 28 years of follow-up

✍ J.-C. Gazet; R. Sutcliffe 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 345 KB

Cost-effectiveness analysis of anastrozo

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB

15 Five years of exemestane as initial t

15 Five years of exemestane as initial therapy compared to tamoxifen followed by exemestane for a total of 5 years: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone receptor-positive early breast cancer

✍ A. Hasenburg; C.J.H. van de Velde; C. Seynaeve; D.W. Rea; J. Vannetzel; R. Parid 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 46 KB